Cargando…

Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335405/ https://www.ncbi.nlm.nih.gov/pubmed/37407238 http://dx.doi.org/10.1136/jitc-2023-006814corr1

Ejemplares similares

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
por: Fa'ak, Faisal, et al.
Publicado: (2023)

Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Publicado: (2021)

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Publicado: (2021)

Correction: T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
Publicado: (2021)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
Publicado: (2017)

Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients
por: Özdemir, Berna C., et al.
Publicado: (2023)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2020)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran
por: Karami, Manoochehr, et al.
Publicado: (2017)

Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy
por: Medina, Patrick, et al.
Publicado: (2019)

Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
por: Weinstein, Alyona, et al.
Publicado: (2017)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
por: Leucht, Katharina, et al.
Publicado: (2022)

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2020)

Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109
por: Zhang, Dongyu, et al.
Publicado: (2022)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_freiv8q71khko3fn9d8m5g4qbo